Conclusion of non-exclusive pharmaceutical discount agreement for Formoterol/Glycopyrronium
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Glycopyrronium (ATC-Code nach WHO: R03AL07)
Opportunity Score
Why this score?
Opportunity
45 / 100
Complexity
30 / 100
Risk factors
No minimum volume guaranteed; actual demand depends on insurer's membership, prescribing behavior, and pharmacy dispens...
Buyer may terminate the Open-House procedure early if exclusive agreements are concluded, ending all non-exclusive agre...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 29, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2028
- Non-exclusive discount agreement for Formoterol/Glycopyrronium
- Pharmaceutical product supply to health insurance fund
Show full summary
Non-exclusive pharmaceutical discount agreement for active substance Formoterol/Glycopyrronium (ATC R03AL07) under an Open-House model, concluded by AOK PLUS (health insurance fund for Saxony and Thuringia). Framework agreement with no exclusivity, no guaranteed volumes, and continuous eligibility for participation until February 2028. Performance in Dresden, Germany. No estimated value provided.
Risks
No minimum volume guaranteed; actual demand depends on insurer's membership, prescribing behavior, and pharmacy dispens...
Buyer may terminate the Open-House procedure early if exclusive agreements are concluded, ending all non-exclusive agre...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG
Eligibility
- Submission of non-exclusion declaration (GWB §§123, 124)
Administrative
- Submission of Russian sanctions declaration (EU Regulation 833/2014)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive pharmaceutical discount agreement for Formoterol/Glycopyrronium
Non-exclusive framework agreement for discount on pharmaceutical product Formoterol/Glycopyrronium (ATC R03AL07) under Open-House model. Performance in Dresden, Saxony/Thuringia. Ongoing enrollment.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Glycopyrronium (ATC-Code nach WHO: R03AL07)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 15 Jan 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 31347-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
45 / 100
Complexity
30 / 100
Risk factors
No minimum volume guaranteed; actual demand depends on insurer's membership, prescribing behavior, and pharmacy dispens...
Buyer may terminate the Open-House procedure early if exclusive agreements are concluded, ending all non-exclusive agre...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications